Study
Number of patients
Treatment
Assay
MGMT status (frequency, %)
Survival
p
PFS
OS
PFS
OS
Newly diagnosed glioblastoma
Jaeckle et al. 1998
40
SR-RT-BCNU
Protein expression: quantative
immunofluorescence
Low level: 33 % (≤ 60,000 molecules/nucleus)
12 mo
0.0002
High level: 67 % (> 60,000 molecules/nucleus)
7 mo
Kamiryo et al. 2004
74
SR-RT-PAV/SR-RT-PAV-IFNβ
DNA methylation
Me: 45 %
0.42 years
1.69 years
0.98
0.20
Um: 55 %
0.43 years
1.34 years
Hegi et al. 2005
206
SR-CCRT-TMZ
DNA methylation
Me: 45 %
10.3 mo
21.7 mo
< 0.001
Um: 55 %
5.3 mo
12.7 mo
SR-RT-TMZ
Me
5.9 mo
15.3 mo
Um
4.4 mo
11.8 mo
Watanabe et al. 2005
29
SR-RT-ACNU-IFNβ
DNA methylation
Me: 34 %
14 mo
38 mo
0.009
0.008
Um: 66 %
4 mo
7 mo
Herrlinger et al. 2006
19
SR-RT-CCNU-TMZ
DNA methylation
Me: 42 %
19 mo
Not reached
0.014
0.037
Um: 58 %
6 mo
12.5 mo
Criniere et al. 2007
219
SR-RT
DNA methylation
Me: 58 %
10.2 mo
0.407
Um: 42 %
15.1 mo
SR-RT-CT (nitrosourea-based)
Me
17.1 mo
0.049
Um
13.1 mo
SR-CRT (with nitrosourea)/CT (nitrosourea-based)
Me
19.9 mo
0.0004
Um
13.5 mo
Chinot et al. 2007
25 (inoperable glioblastoma)
STB-TMZ/RT-TMZ
Protein expression
Immunonegative: 44 % (< 35 % cells)
5.5 mo
16 mo
0.009
0.003
Immunopositive: 56 % (≥ 35 % cells)
1.9 mo
5 mo
Brandes et al. 2008
103
SR-CCRT-TMZ
DNA methylation
Me: 35 %
21.9 mo
43.6 mo
< 0.0001
< 0.0001
Um: 65 %
9.2 mo
16.8 mo
Capper et al. 2008
73
SR-RT-CT
Protein expression
Immunonegative: 58 % ( < 15 % cells)
15.4 mo
0.0002
Immunopositive: 42 % (> 15 % cells)
8 mo
Smith et al. 2008
22
SR-BCNU (wafer implantation)- GKSRS
DNA methylation
Me: 41 %
103 weeks
0.0009
Um: 59 %
45 weeks
Brandes et al. 2009
58 (elderly patients: ≥ 65 years)
SR-CCRT-TMZ
DNA methylation
Me: 43 %
22.9 mo
Not reached
< 0.01
0.05
Um: 57 %
9.5 mo
13.7 mo
Cao et al. 2009
76
SR-CCRT-TMZ/SR-TMZ after recurrence
DNA methylation
Me: 61 %
19.87 mo
0.014
Um: 39 %
12.3 mo
80
Protein expression
Immunonegative: 60 % (< 5 % cells)
17.43 mo
0.197
Immunopositive: 27.5 % (< 30 % cells)
15.83 mo
Immunopositive: 12.5 % (≥ 30 % cells)
10.67 mo
Clarke et al. 2009
48
SR-RT-dose-dense TMZ/ SR-RT-metronomic TMZ
DNA methylation
Me: 19 %
4.2 mo
28.1 mo
Um: 81 %
5 mo
14.9 mo
Dunn et al. 2009
109
SR-CCRT-TMZ
DNA methylation
Me: 53 %
11.8 mo
16.8 mo
0.0001
0.00001
Um: 47 %
8.3 mo
11.1 mo
Felsberg et al. 2009
66
SR-RT-TMZ
DNA methylation
Me: 39 %
245 days
692 days
0.0003
0.004
Um: 61 %
100 days
474 days
SR (near-complete)-RT-TMZ
Me
268 days
681 days
Um
163 days
507 days
SR (non-complete)-RT-TMZ
Me
166 days
499 days
Um
83 days
406 days
Gerstner et al. 2009
40 (elderly patients: ≥ 70 years)
SR-TMZ/SR-BCNU
DNA methylation
Me: 60 %
405 days
489 days
0.27
0.0021
Um: 40 %
246 days
263 days
Glas et al. 2009
23
SR-RT-TMZ/SR-CCNU
DNA methylation
Me: 48 %
19 mo
34.3 mo
0.0064
0.0009
Um: 52 %
7 mo
12.5 mo
Grossman et al. 2009
24
SR-CCRT-TMZ/talampanel (6 mo)
DNA methylation
Me: 29 %
29.1 mo
Um: 71 %
16.3 mo
Nakagawa et al. 2009
23
SR-RT-ACNU-CBDCA-VP-16-IFN-b
Protein expression
Immunonegative: 70 % (< 10 % cells)
15.3 mo
0.042
Immunopositive: 30 % (≥ 10 % cells)
10 mo
Prados et al. 2009
44
SR-CCRT-TMZ-erlotinib
DNA methylation
Me: 36 %
25.5 mo
0.006
Um: 64 %
14.6 mo
Park et al. 2009
48
SR-RT-ACNU-cisplatin
DNA methylation
Me: 54 %
17 mo
0.56
Um: 46 %
17 mo
Stupp et al. 2009
206
SR-RT
DNA methylation
Me: 45 %
15.3 mo
Um: 55 %
11.8 mo
SR-CCRT-TMZ
Me
23.4 mo
< 0.0001
Um
12.6 mo
Weller et al. 2009
295
SR-RT/SR-RT-TMZ
DNA methylation
Me: 45 %
7.5 mo
18.9 mo
< 0.001 (RT-TMZ)
< 0.001 (RT-TMZ)
Um: 55 %
6.3 mo
11.1 mo
Zawlik et al. 2009
371
SR/SR-RT
DNA methylation
Me: 44 %
10.1 mo
Um: 56 %
10 mo
Ang et al. 2010
105
SR-CRT (with TMZ)/SR-RT
DNA methylation
Me: 54 %
30 weeks
61 weeks
0.01
0.02
Um: 46 %
24 weeks
42 weeks
78
SR-CRT (with TMZ)
Me
71 weeks
Um
42 weeks
25
SR-RT
Me
14 weeks
Um
Not reached
Costa et al. 2010
80
SR-CCRT-TMZ
DNA methylation
Me: 48 %
9 mo
16 mo
0.77
0.58
Um: 52 %
10 mo
13 mo
Etcheverry et al. 2010
50
SR-CCRT-TMZ
DNA methylation
Me: 60 %
26.2 mo
< 0.01
Um: 40 %
9.5 mo
Karayan-Tapon et al. 2010
81
SR-CCRT-TMZ
DNA methylation
Me: 68 %
19 mo
0.005
Um: 32 %
15 mo
81
DNA methylation
Me: 48 %
23 mo
< 0.0001
Um: 52 %
14 mo
79
DNA methylation
Me: 49 %
23 mo
0.0001
Um: 51 %
14 mo
80
RNA expression
Low level: 50 %
20 mo
0.028
High level: 50 %
14 mo
78
Protein expression
Immunonegative: 50 %
17 mo
0.595
Immunopositive: 50 %
17 mo
Minniti et al. 2010
87
SR-CCRT-TMZ
DNA methylation
Me: 36 %
5.6 mo
11.2 mo
0.0001
0.01
Um: 64 %
9.8 mo
16.7 mo
Morandi et al. 2010
159
SR-CCRT-TMZ/SR-RT-TMZ
DNA methylation
Me: 44 %
36 mo
0.004
Um: 56 %
20 mo
Weiler et al. 2010
39
SR-TMZ (1 week on/1 week off) before RT-CCRT-TMZ (1 week on/1 week off) + Indometacin 25 mg twice daily
DNA methylation
Me: 41 %
15.8 mo
Not reached > 21.5 mo
0.0002
0.10
Um: 59 %
6.2 mo
15 mo
Rivera et al. 2010
171
SR-RT
DNA methylation
Me: 32 %
31 weeks
63 weeks
0.009
0.019
Um: 68 %
15 weeks
51 weeks
Stupp et al. 2010
45
SR-CCRT-TMZ-cilengitide
DNA methylation
Me: 51 %
13.4 mo
23.2 mo
< 0.001
0.022
Um: 49 %
3.4 mo
13.1 mo
Sonoda et al. 2010
62
SR-RT-ACNU/SR-RT-TMZ
DNA methylation
Me: 56 %
12 mo
26 mo
0.019
0.40
Um: 44 %
5 mo
17 mo
73
Protein expression
Immunonegative: 36 % (< 20 % cells)
13 mo
43 mo
0.045
0.30
Immunopositive: 64 % (≥ 20 % cells)
7 mo
19 mo
Balañá et al. 2011
70
SR-RT-BCNU/SR-CCRT-TMZ
DNA methylation
Me: 39 %
34.2 weeks
73 weeks
0.03
0.04
Um: 61 %
31.4 weeks
54.7 weeks
Kreth et al. 2011
53
SR-CCRT-TMZ
RNA expression
Low level: 42 %
17.5 mo
21.6 mo
High level: 58 %
3.3 mo
10.4 mo
Lai et al. 2011
70
SR-CCRT-TMZ-BEV
DNA methylation
Me: 41 %
17.5 mo
24.7 mo
< 0.005
< 0.005
Um: 59 %
10.5 mo
15.9 mo
Minniti et al. 2011
83 (elderly patients: ≥ 65 years)
SR-CCRT-TMZ
DNA methylation
Me: 51 %
10.5 mo
15.3 mo
0.0001
0.0001
Um: 49 %
5.5 mo
10.2 mo
Perez-Larraya et al. 2011
31 (elderly patients: ≥ 70 years)
SR-TMZ
DNA methylation
Me: 42 %
26 weeks
31 weeks
0.03
0.03
Um: 58 %
11 weeks
19 weeks
Shah et al. 2011
28
SR-CCRT-TMZ
DNA methylation
Me: 29 %
373 days
0.21
Um: 71 %
224 days
28
DNA methylation
Me: 46 %
540 days
0.007
Um: 54 %
210 days
24
Protein expression
Immunonegative: 58 % (≤ 15 % cells)
540 days
< 0.0001
Immunopositive: 42 % (> 15 % cells)
197 days
Thon et al. 2011
56 (inoperable glioblastoma)
STB-CCRT-TMZ
DNA methylation
Me: 54 %
56 weeks
104 weeks
< 0.0001
< 0.0001
Um: 46 %
20 weeks
28 weeks
Uno et al. 2011
29
SR-RT/SR-RT-BCNU
DNA methylation
Me: 41 %
27.4 mo
0.025
Um: 59 %
12 mo
28
SR-RT/SR-RT-BCNU
DNA methylation
Me: 39 %
31.7 mo
0.004
Um: 61 %
11.8 mo
Zunarelli et al. 2011
77
SR-CCRT-TMZ/SR-RT
DNA methylation
Me: 31 %
17.8 mo
< 0.04
Um: 69 %
11.1 mo
46
SR-CCRT-TMZ
Me: 30 %
20.1 mo
< 0.002
Um: 70 %
12.9 mo
18
SR-RT
Me: 72 %
7.6 mo
Um: 28 %
5.3 mo
Havik et al. 2012
86
SR-CCRT-TMZ
DNA methylation (MSP)
Me: 34 %
17.6 mo
Um: 66 %
12.2 mo
DNA methylation (pyrosequencing)
Me: 51 %
16.1 mo
Um: 49 %
11.5 mo
Kim et al. 2012
78
SR-CCRT-TMZ/SR-RT-TMZ/SR-RT-BCNU, CCNU, VCR
DNA methylation
Me: 45 %
18 mo
29 mo
0.017
0.002
Um: 55 %
9 mo
20 mo
6 (age ≤ 50)
SR (gross-total or subtotal)-CCRT-TMZ/SR-RT-TMZ/SR-RT-BCNU, CCNU, VCR
Me
Not reached (38–77 mo)
13 (age ≤ 50)
Um
24 mo
5 (age ≤ 50)
SR (partial or biopsy)-CCRT-TMZ (6 cycles)/SR-RT-TMZ/SR-RT-BCNU, CCNU, VCR
Me
38 mo
1 (age ≤ 50)
Um
15 mo
20 (age > 50)
SR (gross-total or subtotal)-CCRT-TMZ (6 cycles)/ SR-RT-TMZ/SR-RT-BCNU, CCNU, VCR
Me
21 mo
21 (age > 50)
Um
18 mo
4 (age > 50)
SR (partial or biopsy)-CCRT-TMZ (6 cycles)/SR-RT-TMZ/SR-RT-BCNU, CCNU, VCR
Me
12 mo
8 (age > 50)
Um
13.2 mo
Lechapt-Zalcman et al. 2012
110
SR-BCNU (wafer implantation)-CCRT-TMZ
DNA methylation
Me: 57 %
10.7 mo
21.7 mo
0.155
0.025
Um: 43 %
9.7 mo
15.1 mo
106
Protein expression
Immunonegative: 48 % (< 15 % cells)
11.5 mo
27 mo
0.049
0.021
Immunopositive: 52 % (> 15 % cells)
9.6 mo
15.1 mo
Malmstrom et al. 2012
203 (elderly patients: ≥ 60 years)
SR-TMZ
DNA methylation
Me: 45 %
9.7 mo
0.02
Um: 55 %
6.8 mo
SR-RT
Me
8.2 mo
0.81
Um
7 mo
Niyazi et al. 2012
Related posts:
Biodynamic Phenotypic and Epigenetics Changes of Circulating Tumor Cells: Their Application in Cancer Prognosis and Treatment
An Introduction to Impact of Bio-Resonance Technology in Genetics and Epigenetics
Essence of Cancer Epigenetic: A Harmonic Art for the Future
Malignant Rhabdoid Tumor: Epigenetic Mechanism of Tumorogenesis
Sentinel Gene Within Cell Territory and Molecular Platforms in Cancer: Methylation Diversity of p53 Gene in Brain Tumors
Exploring ATM and Methylation in Cancer: Emphasizing on Brain Tumors
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
Get Clinical Tree app for offline access
